216 related articles for article (PubMed ID: 24392978)
21. A predictive Bayesian approach to the design and analysis of bridging studies.
Gould AL; Jin T; Zhang LX; Wang WW
J Biopharm Stat; 2012 Sep; 22(5):916-34. PubMed ID: 22946940
[TBL] [Abstract][Full Text] [Related]
22. Further discussion on the design and analysis of thorough QTc clinical trials: guest editors' notes.
Tsong Y; Zhang J
J Biopharm Stat; 2010 May; 20(3):493-6. PubMed ID: 20358431
[No Abstract] [Full Text] [Related]
23. Adaptive group sequential test with changing patient population.
Feng H; Liu Q
J Biopharm Stat; 2012; 22(4):662-78. PubMed ID: 22651107
[TBL] [Abstract][Full Text] [Related]
24. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
25. Handling missing data issues in clinical trials for rheumatic diseases.
Wong WK; Boscardin WJ; Postlethwaite AE; Furst DE
Contemp Clin Trials; 2011 Jan; 32(1):1-9. PubMed ID: 20840873
[TBL] [Abstract][Full Text] [Related]
26. Adaptive statistical analysis following sample size modification based on interim review of effect size.
Hung HM; Cui L; Wang SJ; Lawrence J
J Biopharm Stat; 2005; 15(4):693-706. PubMed ID: 16022173
[TBL] [Abstract][Full Text] [Related]
27. Design principles and statistical considerations in periodontal clinical trials.
Koch GG; Paquette DW
Ann Periodontol; 1997 Mar; 2(1):42-63. PubMed ID: 9151542
[TBL] [Abstract][Full Text] [Related]
28. Optimization of adaptive designs: efficiency evaluation.
Menon S; Chang M
J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
[TBL] [Abstract][Full Text] [Related]
29. Adjusted significance levels for subgroup analyses in clinical trials.
Spiessens B; Debois M
Contemp Clin Trials; 2010 Nov; 31(6):647-56. PubMed ID: 20832503
[TBL] [Abstract][Full Text] [Related]
30. Optimal timing for interim analyses in clinical trials.
Togo K; Iwasaki M
J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
[TBL] [Abstract][Full Text] [Related]
31. Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulations.
Lipkovich I; Dmitrienko A; Denne J; Enas G
Stat Med; 2011 Sep; 30(21):2601-21. PubMed ID: 21786278
[TBL] [Abstract][Full Text] [Related]
32. Stopping guidelines for harm in a study designed to establish the safety of a marketed drug.
Fleishman AN; Parker RA
J Biopharm Stat; 2012; 22(2):338-50. PubMed ID: 22251178
[TBL] [Abstract][Full Text] [Related]
33. When to stop treatment arms in a clinical trial assessing time to event with more than two arms against a common control.
Grobler AC; Carrara HR; Mwambi HG; Parker RA
Eval Health Prof; 2007 Sep; 30(3):284-99. PubMed ID: 17693620
[TBL] [Abstract][Full Text] [Related]
34. Analyzing and Interpreting Clinical Trials.
Spino C
Gastroenterology; 2016 Apr; 150(4):797-800. PubMed ID: 26924090
[No Abstract] [Full Text] [Related]
35. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
Schäfer H; Müller HH
Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
[TBL] [Abstract][Full Text] [Related]
36. Statistics and the relationship of clinical research to clinical practice.
Khuder SA; Kahaleh B
J Rheumatol; 2009 Feb; 36(2):219-20. PubMed ID: 19208555
[No Abstract] [Full Text] [Related]
37. Note on special technical issue on adaptive designs for clinical trials.
Liu Q; Chang M
J Biopharm Stat; 2012; 22(4):615-6. PubMed ID: 22651104
[No Abstract] [Full Text] [Related]
38. Pharmacology and statistics: recommendations to strengthen a productive partnership.
Spector R; Vesell ES
Pharmacology; 2006; 78(3):113-22. PubMed ID: 17008772
[TBL] [Abstract][Full Text] [Related]
39. Superiority trials: raising the bar of null hypothesis statistical testing.
Shafiq N; Malhotra S
Evid Based Med; 2015 Oct; 20(5):154-5. PubMed ID: 26337934
[TBL] [Abstract][Full Text] [Related]
40. Design and sample size considerations for simultaneous global drug development program.
Huang Q; Chen G; Yuan Z; Lan KK
J Biopharm Stat; 2012 Sep; 22(5):1060-73. PubMed ID: 22946950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
